Who makes Metarapone?

Metarapone is developed by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What development phase is Metarapone in?

Metarapone is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Metarapone

IRCCS Azienda Ospedaliero-Universitaria di Bologna · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Metarapone
Sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Metarapone CI brief — competitive landscape report
Metarapone updates RSS · CI watch RSS
IRCCS Azienda Ospedaliero-Universitaria di Bologna portfolio CI